Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

495 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune-monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
Tentori CA, Zhao LP, Tinterri B, Strange KE, Zoldan K, Dimopoulos K, Feng X, Riva E, Lim B, Simoni Y, Murthy V, Hayes MJ, Poloni A, Padron E, Cardoso BA, Cross M, Winter S, Santaolalla A, Patel BA, Groarke EM, Wiseman DH, Jones K, Jamieson L, Manogaran C, Daver N, Gallur L, Ingram W, Ferrell PB, Sockel K, Dulphy N, Chapuis N, Kubasch AS, Olsnes AM, Kulasekararaj A, De Lavellade H, Kern W, Van Hemelrijck M, Bonnet D, Westers TM, Freeman S, Oelschlaegel U, Valcarcel D, Raddi MG, Grønbæk K, Fontenay M, Loghavi S, Santini V, Almeida AM, Irish JM, Sallman DA, Young NS, van de Loosdrecht AA, Adès L, Della Porta MG, Cargo C, Platzbecker U, Kordasti S; i4MDS consortium. Tentori CA, et al. Among authors: daver n. Hemasphere. 2024 May 15;8(5):e64. doi: 10.1002/hem3.64. eCollection 2024 May. Hemasphere. 2024. PMID: 38756352 Free PMC article.
Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.
DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. DiNardo CD, et al. Among authors: daver n. Leukemia. 2014 Apr;28(4):958-61. doi: 10.1038/leu.2014.8. Epub 2014 Jan 10. Leukemia. 2014. PMID: 24492324 Free PMC article. No abstract available.
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression.
DiNardo CD, Jabbour E, Ravandi F, Takahashi K, Daver N, Routbort M, Patel KP, Brandt M, Pierce S, Kantarjian H, Garcia-Manero G. DiNardo CD, et al. Among authors: daver n. Leukemia. 2016 Apr;30(4):980-4. doi: 10.1038/leu.2015.211. Epub 2015 Jul 31. Leukemia. 2016. PMID: 26228814 Free PMC article. No abstract available.
BRAF mutation in myeloid neoplasm: incidences and clinical outcomes.
Abuasab T, Mohamed S, Pemmaraju N, Kadia TM, Daver N, DiNardo CD, Ravandi F, Qiao W, Montalban-Bravo G, Borthakur G. Abuasab T, et al. Among authors: daver n. Leuk Lymphoma. 2024 Sep;65(9):1344-1349. doi: 10.1080/10428194.2024.2347539. Epub 2024 May 2. Leuk Lymphoma. 2024. PMID: 38696743
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. Montalban-Bravo G, et al. Among authors: daver n. Leukemia. 2017 Feb;31(2):318-324. doi: 10.1038/leu.2016.303. Epub 2016 Oct 31. Leukemia. 2017. PMID: 27795561 Clinical Trial.
Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.
Boddu P, Jorgensen J, Kantarjian H, Borthakur G, Kadia T, Daver N, Alvarado Y, Pemmaraju N, Bose P, Naqvi K, Yilmaz M, Pierce S, Brandt M, DiNardo CD, Jabbour EJ, Konopleva M, Garcia-Manero G, Cortes J, Ravandi F. Boddu P, et al. Among authors: daver n. Leukemia. 2018 Jan;32(1):241-244. doi: 10.1038/leu.2017.285. Epub 2017 Sep 18. Leukemia. 2018. PMID: 28919634 No abstract available.
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Daver N, Kantarjian H, Ravandi F, Estey E, Wang X, Garcia-Manero G, Jabbour E, Konopleva M, O'Brien S, Verstovsek S, Kadia T, Dinardo C, Pierce S, Huang X, Pemmaraju N, Diaz-Pines-Mateo M, Cortes J, Borthakur G. Daver N, et al. Leukemia. 2016 Feb;30(2):268-73. doi: 10.1038/leu.2015.244. Epub 2015 Sep 14. Leukemia. 2016. PMID: 26365212 Free PMC article. Clinical Trial.
Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation.
Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Chen Y, et al. Among authors: daver n. Leukemia. 2013 Apr;27(4):836-42. doi: 10.1038/leu.2012.319. Epub 2012 Nov 8. Leukemia. 2013. PMID: 23135353 Free PMC article.
Influence of IDH on FLT3-ITD status in newly diagnosed AML.
Boddu P, Takahashi K, Pemmaraju N, Daver N, Benton CB, Pierce S, Konopleva M, Ravandi F, Cortes J, Kantarjian H, DiNardo CD. Boddu P, et al. Among authors: daver n. Leukemia. 2017 Nov;31(11):2526-2529. doi: 10.1038/leu.2017.244. Epub 2017 Jul 28. Leukemia. 2017. PMID: 28751773 No abstract available.
495 results